Acquisition of Nanogenics Ltd

2024-02-20T16:22:26+00:00September 29th, 2023|Blog, N4 Pharma Investor Presentations, News|

N4 Pharma is pleased to announce the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary lipid and peptide-based delivery system called LipTide®, which it is using to develop a novel siRNA product targeting an unmet clinical need in [...]